Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00765323 · ClinicalTrials.gov registry record · Phase 3

Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly

A Phase 3 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.

Terminated
Registry status
Phase 3
Development phase
169
Enrollment target

NCT00765323: Clinical Trial Phase 3 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.

NCT00765323 is a Phase 3 study that was terminated before completion, run by Endo USA Inc., a Keenova Therapeutics Company. The registered enrollment target is 169 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00765323, a Phase 3 study, was terminated before completion, sponsored by Endo USA Inc., a Keenova Therapeutics Company.

TERMINATED
Registry status
Phase 3
Development phase
169 participants
Enrollment target

Study Summary

Evaluate the efficacy, safety and tolerability of the octreotide implant in patients with acromegaly that were previously treated with octreotide depot.

Interventions

  • DRUG Sandostatin LAR Depot
  • DRUG Octreotide Implant

Trial Details

FieldValue
Enrollment Target 169 participants
Start Date 2008-09
Est. Completion 2011-06
Phase Phase 3

Why NCT00765323 stopped before completion

NCT00765323 is an interventional study that assigns participants to a tested intervention. The registered 169 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (78% lower).

The record links to 0 conditions, and to 2 interventions - of which Sandostatin LAR Depot is the first listed.

NCT00765323 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00765323 about?

NCT00765323 is a clinical study titled "Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly". Evaluate the efficacy, safety and tolerability of the octreotide implant in patients with acromegaly that were previously treated with octreotide depot.

What is the current status of trial NCT00765323?

This trial is currently terminated. It is a Phase 3 study. The enrollment target is 169 participants. The study started on 2008-09. Estimated completion is 2011-06.

What interventions are being tested in trial NCT00765323?

The interventions under investigation include: Sandostatin LAR Depot (DRUG), Octreotide Implant (DRUG).

Who is sponsoring clinical trial NCT00765323?

This trial is sponsored by Endo USA Inc., a Keenova Therapeutics Company, which has 61 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00765323's enrollment target sits among peer trials

169 1459th of 2000 higher than 542 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06191484 · 169 participants · NA

    Risk and Resilience to Suicide Following Late-Life Spousal Bereavement

  • NCT02016430 · 170 participants · NA

    Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)

  • NCT02621021 · 170 participants · Phase 2

    A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab

  • NCT04094701 · 170 participants · NA

    Hip Arthroscopy Postoperative Opioid Demands

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00765323, the US trial registry maintained by the National Library of Medicine. NCT00765323 (mid enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.